tirzepatide backorder FDA declares Mounjaro, Zepbound shortage over Compounders protest as FDA removes

Due to how common obesity is in the United States as well as the cost implications, if and when GLP-1 drugs are covered is a primary area of focus

The agreement calls for further price reductions over the next two years, and lower prices ($150) for oral GLP-1 medications when they are approved for obesity and become available

It is also commonly prescribed off-label (for non-FDA-approved use) to help with weight loss and weight management in people with obesity or who are overweight with weight-related medical conditions

Inflammation is one of the first signs of autoimmune disease, which is a cause of restless legs syndrome